EU Clinical Trial 2017-001205-33

A Phase III Open-label Safety and Immunogenicity Study of GARDASIL™9 Administered to 9- to 26-Year-Old Females and Males in Vietnam  Mar 14, 2019

Main objective of the trial: In 9- to 26-year-old female and male participants: To demonstrate that the 9vHPV vaccine is immunogenic

Parties

Sponsors
Countries
EU VN
Keywords
GARDASIL®9 Human Papillomavirus 9-valent Vaccine (Recombinant, adsorbed) Human papilloma virus infection

JSON preview

Similar records

Title

Source:  EMA Last updated:  May 30, 2019

From ClinicalTrialsRegister.eu, a database of the European Medicines Agency. This record may not reflect the most current and accurate data available from the EMA.